Issue Date: April 28, 2014
Valeant Makes Hostile Bid For Allergan
Valeant Pharmaceuticals has made a $47 billion cash-and-stock offer to buy specialty pharmaceuticals maker Allergan in a deal backed by activist investor William A. Ackman.
Adding Allergan’s $6.3 billion in 2013 sales to Valeant would create a firm with revenues of $11.7 billion. Valeant would save some $2.7 billion by combining headquarters, eliminating duplicative operations, and cutting research spending.
Allergan, the maker of Botox wrinkle reducer, says it is examining Valeant’s . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society